Xenon Pharmaceuticals

XENE · Nasdaq · Canada

Share price · XENE

$37.75-25.43 (-40.25%) 3M

close as of 2026-11-18 · 24h delayed · vol 1.4M (1.0x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when XENE's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 18 Sep 2026-30.7%
  2. 26 Aug 2026+5.6%
  3. 8 Jul 2026+10.4%
  4. 9 Mar 2026+49.6%
  5. 27 Feb 2026-3.8%
  6. 24 Feb 2026+4.8%
  7. 5 Jan 2026-6.1%

Share of unusual movement by asset

For each asset, the share of XENE's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 3
Kv7 potassium channelSmall molecule
Major Depressive DisorderEpilepsy
Focal Onset Seizures, Primary Generalized Tonic-Clonic Seizures

Upcoming events

(7 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (3)
January 2027 (1)
AzetukalnerPhase 3Major Depressive Disorder
Est. primary completion 2027-01 · NCT06922110 · CT.gov ↗
What to watch
April 2027 (1)
AzetukalnerPhase 3Primary Generalized Tonic-Clonic Seizures
Est. primary completion 2027-04 · NCT05667142 · CT.gov ↗
What to watch
May 2027 (1)
AzetukalnerPhase 3Major Depressive Disorder
Est. primary completion 2027-05 · NCT07076407 · CT.gov ↗
What to watch
2028 (2)
January 2028 (1)
AzetukalnerPhase 3Focal Onset Seizures
Est. primary completion 2028-01 · NCT05716100 · CT.gov ↗
What to watch
June 2028 (1)
AzetukalnerPhase 3Bipolar Disorder, Bipolar Depression, Bipolar I Disorder, Bipolar II Disorder
Est. primary completion 2028-06 · NCT07172516 · CT.gov ↗
What to watch
2029 (1)
June 2029 (1)
AzetukalnerPhase 3Bipolar Depression, Bipolar I Disorder, Bipolar Disorder, Bipolar II Disorder
Est. primary completion 2029-06 · NCT07217860 · CT.gov ↗
What to watch
2033 (1)
April 2033 (1)
AzetukalnerPhase 3Focal Epilepsy, Tonic-Clonic Seizures
Est. primary completion 2033-04 · NCT05718817 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

17 September 2026Filing submittedAzetukalnerAzetukalner NDA submitted
US, FDA · Xenon Pharmaceuticals · Source ↗
9 March 2026Topline resultAzetukalnerPhase 3 X-TOLE2 (NCT05614063) of azetukalner met its primary endpoint
Xenon Pharmaceuticals · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$0$96M$83M+ $868M short-term inv.$110M-$90M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$0$99M$120M+ $811M short-term inv.$111M-$95M operating cash flowreport ↗
2026-Q1$0$89M$546M+ $549M short-term inv.$102M-$89M operating cash flowreport ↗
2025-Q3$0$77M$105M+ $358M short-term inv.$91M-$72M operating cash flowreport ↗
2025-Q2$0$75M$135M+ $352M short-term inv.$85M-$64M operating cash flowreport ↗
2025-Q1$7.5M$61M$117M+ $433M short-term inv.$65M-$62M operating cash flowreport ↗
2024-Q3$0$57M$88M+ $566M short-term inv.$63M-$51M operating cash flowreport ↗
2024-Q2$0$50M$137M+ $585M short-term inv.$58M-$33M operating cash flowreport ↗
2024-Q1$0$44M$59M+ $641M short-term inv.$48M-$43M operating cash flowreport ↗
2023-Q3—$43M$100M+ $427M short-term inv.$48M-$42M operating cash flowreport ↗
2023-Q2—$44M$65M+ $475M short-term inv.$47M-$33M operating cash flowreport ↗
2023-Q1—$40M$70M+ $458M short-term inv.$42M-$34M operating cash flowreport ↗
2022-Q3$0.1M$29M$103M+ $535M short-term inv.$37M-$30M operating cash flowreport ↗
2022-Q2$0.5M$22M$370M+ $418M short-term inv.$31M-$17M operating cash flowreport ↗
2022-Q1$8.8M$19M$117M+ $421M short-term inv.$20M-$18M operating cash flowreport ↗
2021-Q3$8.1M$19M$88M+ $162M short-term inv.$15M-$15M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$7.5M$301M$199M+ $350M short-term inv.$86M-$279M operating cash flowreport ↗

Xenon reported fiscal 2025 revenue of $7.5M, versus $0M YoY. R&D expense was $300.94M, up 43.0% YoY, cash and equivalents were $199.16M, and cash plus marketable securities totaled $586.0M at Dec. 31, 2025. Net loss was $345.91M, with a reported quarterly net burn of $345.91M.

Management guided that pro forma cash of $716.0M, including ATM proceeds, funds operations into the second half of 2027. Pipeline milestones include Phase 3 X-TOLE2 topline data for azetukalner in focal onset seizures expected in the first half of March 2026, an anticipated NDA submission in H2 2026, X-NOVA2 MDD topline data expected in H1 2027, and Phase 1 data for XEN1701 and XEN1120 expected in 2026. Enrollment continues across X-TOLE3, X-ACKT, X-NOVA3, and X-CEED; 48-month X-TOLE open-label extension data were presented at AES, and a partnered Phase 1 study of NBI-921355 with Neurocrine is ongoing.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$0$210M$143M+ $484M short-term inv.$59M-$181M operating cash flowreport ↗
2023-FY$0$168M$149M+ $489M short-term inv.$46M-$145M operating cash flowreport ↗
2022-FY$9.4M$106M$57M+ $535M short-term inv.$31M-$98M operating cash flowreport ↗
2021-FY$18M$75M$176M+ $376M short-term inv.$20M-$70M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 2 purchases ($1.7M), 26 sales ($22.0M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-10-15Kelly Thomas Patrick · Chief Financial OfficerOption exercise7,500——Form 4
2026-10-15Kelly Thomas Patrick · Chief Financial OfficerOption exercise (derivative)7,500——Form 4
2026-09-30MORTIMER IAN · director, PRESIDENT & CEOOpen-market purchase30,000$37.38$1.1MForm 4
2026-09-30Kelly Thomas Patrick · Chief Financial OfficerOpen-market purchase15,000$37.32$560KForm 4
2026-09-01Svoronos Dawn · directorOption exercise5,144$8.15$42KForm 4
2026-09-01Svoronos Dawn · directorOption exercise (derivative)5,144——Form 4
2026-08-28KENNEY CHRISTOPHER JOHN · Chief Medical OfficerOpen-market sale6,368$60.17$383KForm 4
2026-08-28KENNEY CHRISTOPHER JOHN · Chief Medical OfficerOpen-market sale700$60.98$43KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 288 reporting institutions held 100.3M shares ($5.6B, 103.8% of shares outstanding).

#InstitutionSharesValue
1FMR LLC10,818,491$629.1M
2Avoro Capital Advisors LLC5,777,777$336.0M
3BlackRock, Inc.5,640,118$328.0M
4WELLINGTON MANAGEMENT GROUP LLP4,829,641$280.8M
5Driehaus Capital Management LLC4,491,653$261.2M
6Polar Capital Holdings Plc4,405,312$256.2M
7JANUS HENDERSON GROUP PLC4,175,982$242.9M
8Capital International Investors2,674,727$155.5M
9CITADEL ADVISORS LLC2,652,990$154.3M
10JPMORGAN CHASE & CO1,923,610$106.9M
11STATE STREET CORP1,720,533$100.0M
12Affinity Asset Advisors, LLC1,675,000$97.4M
13DEERFIELD MANAGEMENT COMPANY, L.P.1,615,696$94.0M
14Holocene Advisors, LP1,518,686$88.3M
15WESTFIELD CAPITAL MANAGEMENT CO LP1,401,483$81.5M